RVNC - Revance signs supply agreement with contract manufacturer Lyophilization

Revance Therapeutics (RVNC) has inked a commercial supply agreement with Lyophilization Services of New England, a contract development and manufacturing services organization.Per the terms of the arrangement, Lyophilization will become a non-exclusive manufacturer and supplier of the company’s future products that are currently undergoing development.“The supply agreement provides the company with an additional source of drug manufacturing to support clinical development and commercialization of the products to potentially mitigate supply chain risk,” Revance said in a regulatory filing.The costs estimated at $28M for the design, equipment procurement, and validation and facilities-related costs will be paid by the company based on the achievement of pre-specified milestones.In February, Revance announced positive Phase 2 data for DaxibotulinumtoxinA for injection for adults with upper limb spasticity.

For further details see:

Revance signs supply agreement with contract manufacturer Lyophilization